论文部分内容阅读
目的观察供者表达活化性杀伤细胞免疫球蛋白样受体(aKIR)对受者造血干细胞移植(HSCT)预后的影响。方法1996年至2001年共行亲缘性人类白细胞抗原(HLA)全相合骨髓移植59例,以序列特异性引物多聚酶链反应法(SSP-PCR)检测供者aKIR的表型。分析供者表达aKIR对受者移植后病毒、细菌和真菌感染及出血、复发、存活情况的影响。结果供者表达aKIR与受者移植后出血、病毒及细菌感染发生的概率无明显相关性;当供者表达KIR3DS1表型时,发生真菌感染概率增高(χ2=4.804,P=0.028)。供者表达aKIR对受者HSCT后存活率和白血病复发率均无明显影响。结论亲缘性HLA全相合HSCT中,供者表达aKIR并不能改善受者的移植效果。
Objective To investigate the effect of akir on the prognosis of recipients of hematopoietic stem cell transplantation (HSCT) by expressing donor-activated immunoglobulin-like receptor (aKIR). Methods From 1996 to 2001, 59 HLA-matched allogeneic bone marrow transplantation patients were performed. The phenotypes of donor aKIR were detected by sequence-specific polymerase chain reaction (SSP-PCR). The effects of aKIR expressing donor on virus, bacterial and fungal infection, bleeding, recurrence and survival after transplantation were analyzed. Results There was no significant correlation between the expression of aKIR in donor and the probability of hemorrhage, virus and bacterial infection after donor transplantation. The probability of fungal infection increased when donor expressed KIR3DS1 phenotype (χ2 = 4.804, P = 0.028). The expression of aKIR in donor showed no significant effect on the survival rate of recipients after HSCT and the relapse rate of leukemia. Conclusions Affinity aKIR can not improve the recipient’s transplantation effect in allogeneic HLA-matched HSCT.